FAQ: Strait of Hormuz Reopening — What It Means for Pharma Supply Chains

After more than three months of closure that exposed vulnerabilities in global pharmaceutical supply chains, the Strait of Hormuz could reopen following a US-Iran framework agreement announced June 15. What does that mean for drug supply, freight, and long-term resilience? Here's what pharma needs to know.

What happened, and why does it matter to pharma?

The US and Iran reached a framework agreement on June 15 to end their war and reopen the Strait of Hormuz, with a formal signing set for Friday in Switzerland. President Trump announced the deal Sunday and said ships were already beginning to move through the waterway.¹ The strait had been effectively closed since early March 2026, cutting off a chokepoint through which 20–25% of global maritime oil trade flows.² For pharma, the closure triggered months of rising input costs, freight disruptions, and mounting concern over generic drug availability in the US.²

Why did a Middle East shipping lane affect pharmaceutical supply chains at all?

The connection is less obvious than it appears. The US gets nearly 47% of its generic prescriptions and 15% of the volume of biosimilars from India.³ India, in turn, depends on the Strait of Hormuz for around 40% of its crude oil imports, and that oil feeds directly into the petrochemical inputs used throughout pharmaceutical manufacturing.⁴ The dependency doesn't stop at APIs: pharmaceutical supply chains also rely on petrochemical inputs, petroleum-based packaging materials, and logistics systems all tied, directly or indirectly, to the free flow of energy and goods through the Middle East.²

Were generic drugs really at risk? What specific products were most exposed?

Yes, though the timeline for meaningful impact was measured in weeks, not days. Because most pharmacies and wholesalers operate on a just-in-time inventory model for generics, sustained disruption could have started showing up for consumers within four to six weeks — first as shortages or delays for high-volume medications, and potentially extending to some temperature-sensitive therapies.⁴ Specific ingredients were also flagged as particularly vulnerable, like glycerin and phenol derivatives, which originate from petrochemical processes.²

Now that the strait is reopening, does that mean pharma supply chains will normalize quickly?

Not immediately. Oil prices fell roughly 5% on news of the deal, but shippers remained cautious. Additionally, ensuring the waterway is clear of mines could take weeks.¹ The formal agreement won’t be signed until Friday, and Lebanon remains a complicating variable — Iran's foreign ministry stated that Lebanon is an integral part of the agreement, while Israel, which was not party to the negotiations, has been fighting Hezbollah in the county.¹ On the commercial side, Iran's Fars news agency reported the draft deal recognizes Iranian-Omani authority over navigation services in the strait, and Iran has agreed to allow free passage throughout the strait for 60 days – after which, Tehran plans to collect revenue.¹ That uncertainty means freight planning for pharmaceutical shipments remains complex in the near term.

What are the longer-term supply chain implications for pharma, even with the strait reopening?

The disruption exposed structural vulnerabilities that a reopening alone won't resolve. The globalized, just-in-time model for critical goods like generic drugs and ingredients is exposed to single points of failure, and this fragility could accelerate structural shifts toward nearshoring or reshoring of API production.⁵ Some movement is already underway: Lupin, a major Indian generics manufacturer, announced plans to invest $250 million to build a new production facility in Coral Springs, Florida, focused on respiratory drugs.⁴ On the policy side, true diversification — particularly for commodity chemicals and critical inputs — is likely to require government support, whether through incentives for domestic or diversified production, stockpiling strategies, or coordinated international frameworks.²

What should supply chain executives be doing now?

The reopening provides a window, but not a reprieve. Companies must continue mapping their supply chain dependencies across the full production ecosystem and identify short-, medium-, and long-term action plans to diversify identified choke points.² Near-term cost efficiency should be weighed against the long-term costs of supply chain vulnerabilities: diversifying suppliers, building redundancy, and maintaining strategic inventories carry up-front costs, but as recent years have shown, the cheapest supply chain is only cost-effective until it fails.² The months-long Hormuz closure could become a benchmark event in pharmaceutical supply chain risk planning, reflecting how quickly supply-demand imbalances can cascade.

References

1. Hafezi, Parisa, Yomna Ehab, and Maya Gebeily. "Iran, US Agree to Halt War and Reopen Hormuz." Reuters, June 15, 2026. https://www.reuters.com/world/asia-pacific/iran-us-agree-halt-war-reopen-hormuz-sending-oil-prices-tumbling-2026-06-15/
2. Ritter, Geralyn, and Monica Gorman. "Pharmaceutical Risks in the Strait of Hormuz." Pharmaceutical Executive, April 29, 2026. https://www.pharmexec.com/view/pharmaceutical-risks-the-strait-of-hormuz
3. IQVIA Institute for Human Data Science. "U.S.-India Medicine Partnership: India's Contribution to the U.S. Healthcare System." IQVIA, April 30, 2024. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-india-medicine-partnership.
4. Williams, Kevin. "Strait of Hormuz Standoff Puts Supply of America's Generic Drug Prescriptions at Risk." CNBC, March 16, 2026. https://www.cnbc.com/2026/03/16/strait-of-hormuz-closure-generic-drug-prescriptions.html.
5. Jacobus, Nicholas. "Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report." Pharmaceutical Executive, April 7, 2026. https://www.pharmexec.com/view/medical-supply-chains-risk-over-escalating-conflicts-iran-report.